Navigation Links
De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
Date:10/29/2013

est une étape importante pour la réduction de la morbidité et de la mortalité associée à l'ICD », déclare le professeur Oliver Cornely de l'hôpital universitaire de Cologne en Allemagne. « J'approuve ces directives et je pense que l'application de ces recommandations améliorera le traitement de l'ICD et réduira le fardeau à la fois pour les patients et les systèmes de santé. »

Deux importantes études cliniques de phase III comparant l'efficacité et l'innocuité de 400 mg par jour fidaxomicine par voie orale à 500 mg par jour de vancomycine ont permis de montrer les avantages potentiels de la fidaxomicine par rapport à la vancomycine qui est le traitement habituel.[9],[11] Les patients participant à ces essais présentaient un diagnostic confirmé d'ICD et incluaient des patients classés comme souffrant d'une ICD grave ainsi que des patients pour lesquels l'ICD constituait un risque particulièrement important comme les personnes âgées[11] ou avec des pathologies concomitantes.[12],[13],[14] La fidaxomincine a permis de réduire considérablement le taux de récurrence de l'ICD comparé à la vancomycine et les patients traités avec la fidaxomicine étaient plus susceptibles de ne plus souffrir de diarrhées sans récurrence 30 jours après la fin du traitement, que les patients traités avec de la vancomycine.[9],[11] La fidaxomicine a également atteint son critère d'évaluation principal de taux de guérison clinique qui était équivalent à celui de la vancomycine.[9],[11]

Certaines populations courent un risque plus élevé d'ICD et sont particulièrement vulnérables. L'ICD peut être as
'/>"/>

SOURCE Astellas Pharma Europe Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Medicare Procurement Program Creates Extreme Hardships For North Carolina Patients, Says AAHomecare
2. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
3. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
4. 3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Medicare Procurement Program Creates Extreme Hardships for Patients without Options, Says AAHomecare
7. Media Sourcerys Secure Mobile Workflow App Deployed by CCS Medical to Expedite Product Delivery to Patients
8. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
11. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... HERZLIYA PITUACH, Israel , Dec. 15, 2014 ... IMNP ) announced today that its Board of Directors has ... Daniel Teper who continues as Chief Executive Officer ... Board of Directors since 2013. Immune,s new Chairman, ... represent the interest of shareholders and to continue to support ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ), ... small molecule drugs for the treatment of cancer and ... host a conference call and live audio webcast on ... the company,s second quarter fiscal 2011 financial and operational ...
... Health today announced that its board of directors has approved a ... to shareholders of record on April 1. This marks the 106th ... Cardinal Health Headquartered in Dublin, Ohio, Cardinal ... health care services company that improves the cost-effectiveness of ...
Cached Medicine Technology:Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011 2Cardinal Health Declares Regular Quarterly Dividend 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... CITY, Iowa, May 6 Quatro Composites, ... composite products, has been,awarded ISO 9001:2000 and ... of its facilities, located in Orange City, ... of the AS9100 quality management,system., "Receiving ...
... 20% Year-Over-Year ... Cost Reduction Efforts Show ... Ends the Quarter with $10.5 Million in Cash, MONROVIA, Calif., May ... and marketer of,minimally invasive ophthalmic products, today reported good progress during,its first ...
... finds short-term dysfunction while awaiting operation rarely turns ... -- Few patients who have short-term kidney dysfunction ... problems once they have their transplant, says a ... have kidney dysfunction while awaiting liver transplantation, which ...
... Demonstrate to Protect Their Voice & Vote at,SEIU Hearing, ... the direction of the Service Employees International Union (SEIU),intensified ... was held to,determine the fate of more than 60,000 ... West (UHW). UHW represents 150,000,caregivers in hospitals, clinics, nursing ...
... Management: Making a ... Difference Today and Tomorrow, HARRISBURG, Pa., ... Officer, will deliver the clinical keynote,address on Wednesday afternoon, May ... World of Care Management. Dr. Petrulis will,present Care Management: Making ...
... aid couples trying to conceive , , TUESDAY, May 6 ... the lubricant they use wisely because some lubricants can ... commercial lubricants are toxic to sperm, and couples who ... they want," said study author Dr. William H. Kutteh, ...
Cached Medicine News:Health News:Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification 2Health News:STAAR Surgical Reports Solid First Quarter Progress 2Health News:STAAR Surgical Reports Solid First Quarter Progress 3Health News:STAAR Surgical Reports Solid First Quarter Progress 4Health News:STAAR Surgical Reports Solid First Quarter Progress 5Health News:STAAR Surgical Reports Solid First Quarter Progress 6Health News:STAAR Surgical Reports Solid First Quarter Progress 7Health News:STAAR Surgical Reports Solid First Quarter Progress 8Health News:STAAR Surgical Reports Solid First Quarter Progress 9Health News:STAAR Surgical Reports Solid First Quarter Progress 10Health News:STAAR Surgical Reports Solid First Quarter Progress 11Health News:STAAR Surgical Reports Solid First Quarter Progress 12Health News:Kidney Trouble Short-Lived in Most Liver Transplant Patients 2Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 3
... growth factor I (IGF-I or somatomedin C) is ... liver. It acts as a potent mitogen of ... specific cell-surface receptors. In the circulation, IGF-I is ... regulate the actions of IGF-I by modulating the ...
... potent naturally occurring androgen produced from ... 5a-reductase [1]. The concentrations of ... tissues, including genital skin and hair ... apparent association with the nuclear membrane. ...
Urovac bladder evacuator with adaptor...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Medicine Products: